   
Stryker ENT  
 
 
ClariFix Rhinitis Randomized Controlled Trial  
 
 
Investigational Plan Number 4666 -001-rB 
  
20 August  2019  
 
 
Stryker ENT  
3600 Holly Lane  N, Suite 40 
Plymouth, MN  55447  
 
 
This study will be conducted in accordance with the protocol , Good Clinical Practices,  and 
applicable regulatory requirements.  
  
CONFIDENTIAL INFORMATION 
This Clinical Investigational Plan and all attachments are considered confidential information. The 
contents must not be disclosed, unless authorized in writing by Stryker ENT , except to the appropriate 
Institutional Review Board (IRB) or a duly authorized representative of the US Food and Drug 
Administration (FDA) with similar requests for maintenance of confidentiality .  
Clinical Investigational Plan   Page ii  
4666- 001-rB Stryker ENT – C onfidential  Investigator Signature Page  
 
ClariFix Rhinitis Randomized Controlled Trial  
Protocol #4666- 001-rB 
20 August  2019  
 
1. I have read this protoc ol and agree to adhere to its  requirements.  
2. I understand this protocol, including any amendments or associated documents provided with 
the protocol, contains information that is confidential and proprietary to the sponsor. 
3. I will provide this protocol and all pertinent information to the study personnel under my supervision. My study personnel will keep the protocol and associated documents 
confidential.  
4. I will not start enrollment in the study until it is approved by a governing Institutional 
Review Board  (IRB) . 
5. I understand that the study may  be terminated or enrollment suspended at any time by the 
sponsor, with or without cause, or by me if it becomes necessary to protect the interests of the study participants.  
6. I will provide copies of this  protocol and all pertinent information to the authorized IRB to 
ensure they are fully informed regarding the conduct of this study according to this protocol, 
applicable regulatory requirements  (including 21 CFR parts 50 and 56), and IRB 
requirements.  
 
Read and acknowledge by signature below:  
 
____________________________________ Clinical Site Name  
 
_____________________________________ 
Site Principal Investigator Printed Name  
 _____________________________________ _____________________ 
Site Principal In vestigator Signature    Date  
  
Clinical Investigational Plan   Page iii  
4666- 001-rB Stryker ENT – C onfidential  Study Contact Information  
Study Sponsor:  
Stryker ENT  
3600 Holly Lane N, Suite 40 
Plymouth, MN  55447  
Study Contact:  
Stryker ENT Clinical Affairs  
3600 Holly Lane North, Suite 40 Plymouth, MN 55447  
Phone:  (763) 463- 1595  
Email: robyn.schacherer@stryker.com  
Investigational Plan Summary  
Short t itle: ClariFix Rhinitis Randomized Controlled Trial  
Complete title:  A randomized, controlled, single -blinded study compar ing outcomes after 
treatment with the ClariFix cryotherapy dev ice with outcomes after a sham 
treatment in patients with chronic rhinitis  
Study device:  ClariFix® Cryotherapy device  
Study design:  A prospective, multicenter , randomized,  sham -controlled , single -blinded  study  
Enrollment:  A total of 128 research participants randomized 1 :1 to active treatment or sham 
control  
Treatment:  1. Active : treatment with the ClariFix® device  
2. Control:  sham procedure with a ClariFix device minus the cryogen 
cannister  
Clinical  centers : Up to 12 US investigational centers  
Inclusion 
criteria:  Participants  MUST : 
1. Be ≥ 21 years of age . 
2. Has been diagnosed with chronic nonallergic or allergic rhinitis . 
3. Have moderate to severe symptoms of rhinorrhea (individual  reflective 
Total Nasal Symptoms Score [rTNSS]  symptom rating of 2 or 3), mild to 
severe symptoms of nasal congestion (individual rTNSS symptom rating of 
1, 2, or 3), and a minimum total rTNSS of 4 (out of 12) at baseline . 
4. Have an allergy test (by skin prick or intradermal testing or by validated in 
vitro  tests for specific Immunoglobin E [ IgE]) on file within 12 months  of 
the baseline  visit . 
5. Be an appropriate  candidate for bilateral ClariFix treatment performed 
under local anesthesia . 
Clinical Investigational Plan   Page iv  
4666- 001-rB Stryker ENT – C onfidential  6. Be willing and able to comply with all study elements, as indicated by their 
written informed consent . 
Exclusion 
criteria:  Participants  MUST NOT:  
1. Have clinically significant anatomic obstructions that in the investigator’s 
opinion limit access to the posterior nose, including but not limited to 
severe septal deviation or perforation, nasal polyps, and/or sinonasal tumor . 
2. Have  had previous  sinus or nasal surgery within 6 months of study 
enrollment . 
3. Have previously undergone cryotherapy or other surgical interventions for rhinitis.  
4. Have an  active nasal or sinus infection . 
5. Have  rhinitis symptoms that are primarily due to seasonal allergies.  
6. Have plans to (or otherwise anticipates the need to) undergo a n ENT 
procedure concurrently or within 3 months after the study procedure.  
7. Is on prescribed anticoagulants (eg, warfarin, Plavix) or 325 mg aspirin that 
cannot be discontinued before the procedure (8 1 mg aspirin and herbal 
supplements are acceptable).  
8. Be unable to discontinue ipratropium bromide ( IB) at least  14 days before 
baseline and through the 90 -day follow -up vi sit. 
9. Have  a history of chronic epistaxis or experienced a significant epistaxis 
event  (defined as epistaxis requiring medical intervention ) in the past 3 
months . 
10. Have  a history of rhinitis medicamentosa . 
11. Have  had previous head and/or neck irradiation.  
12. Have an allergy or intolerance to local anesthetic agent s.  
13. Have  cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, 
Raynaud’s disease, and/or open and/or infected wounds at or near the target 
tissue . 
14. Have a neurological, medical, psychiatric condition, or social circumstance 
that would potentially increa se risk, interfere with study participation, or 
confound interpretation of study data . 
15. Be participating in another clinical research study . 
Objective:  To demonstrate the superiority of treatment with  the ClariFix cryotherapy 
device compared with a sham procedure in patients  with chronic rhinitis.  
Primary   
endpoint : The p ercentage of responders  at 90 days . Responders are defined as participants 
with a 30% or greater reduction in rTNSS relative to baseline . The active 
treatment group will be compared with the sham -control group.  
Secondary  
endpoint s: The following secondary endpoints will compare the active treatment group 
with the sham -control group at 30- day and 90- day follow -ups: 
• The mean  change  from baseline in rTNSS score . 
• The mean  change  from baseline in  Standardized Rhinoconjunctivitis 
Quality of Life Questionnaire (RQLQ (S)) score.   
Clinical Investigational Plan   Page v  
4666- 001-rB Stryker ENT – C onfidential  • Mean change from baseline in EuroQol 5 -dimension survey ( EQ-5D-5L) 
scores.  
• Percent of patient satisfaction at fo llow-up. 
• The rate of serious device-  and/or procedure -related adverse events . 
The following secondary endpoints will be assessed at all  follow -ups for all 
participants who receive active treatment (randomized or crossover):  
• The percentage of responders  
• The mean change from baseline in rTNSS score  
• The mean change from baseline in  RQLQ(S) score  
• Mean change from baseline in EQ -5D-5L scores  
• Percent of patient satisfaction at follow -up 
Additional exploratory outcomes will be detailed in the Statistical Analysis 
Plan. 
Study 
assessments  • Screening  
• Baseline  
• Randomization and procedure  
• 30-Day postprocedure follow -up 
• 90-Day postprocedure follow -up (unblinding  of initial treatment)  
• 180-Day postprocedure follow -up 
• 270-Day postprocedure follow -up 
• 365-Day postprocedure follow -up 
 
Additionally, sham -control participants will be offered the option to receive 
active treatment after the 90-day follow -up. Those choosing to do so who 
continue to meet the eligibility criteria will then complete all the study 
assessments starting with the new active procedure. Follow -up visits beyond 90 
days are only for participants treated with ClariFix  (randomized or crossover).  
Sponsor:  Stryker ENT , 3600 Holly Lane N, Suite 40, Plymouth , MN 55447  USA 
Data 
management and 
monitoring:  Stryker ENT , 3600 Holly Lane N, Suite 40, Plymouth , MN 55447  USA 
  
Clinical Investigational Plan   Page vi  
4666- 001-rB Stryker ENT – C onfidential  Abbreviations and Acronyms  
AE Adverse event  
CFR  Code of Federal Regulations (US)  
CI Confidence interval  
eCRF  Electronic c ase report form  
EDC  Electronic data collection  
EQ-5D-5L EuroQol -5-dimension survey  (5 level)  
FDA  Food and Drug Administration (US)  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act of 1996 (US)  
IB Ipratropium bromide  (Atrovent)  
ICF Informed Consent Form  
IFU Instructions for use  
IRB Institutional Review Board  
NOSE  Nasal Obstruction Symptom Evaluation scale  
PRO  Patient -reported outcome  
RQLQ (S) Standardized  Rhinoconju nctivitis Quality of Life Questionnaire  
rTNSS  Reflective Total Nasal Symptoms Score  
SAE  Serious adverse event  
US United States of America  
VAS  Visual analog scale  
 
Clinical Investigational Plan   Page 1 of 28  
4666- 001-rB Stryker ENT  – Confidential  Table of Contents  
Investigator Signature Page  ............................................................................................................ ii 
Study Contact Information ............................................................................................................. iii 
Study  Sponsor:  ........................................................................................................................... iii 
Study Contact:  ............................................................................................................................ iii 
Investigational Plan Summary  ....................................................................................................... iii 
Abbreviations and Acronyms  ........................................................................................................ vi 
1 Background and Purpose  ........................................................................................................ 3 
1.1 Background  ...................................................................................................................... 3 
1.2 Report of prior investigations  ........................................................................................... 4 
1.3 Purpose  ............................................................................................................................. 4 
2 Protocol  ................................................................................................................................... 4 
2.1 Study design ..................................................................................................................... 4 
2.2 Study objective  ................................................................................................................. 5 
 Primary objective  ...................................................................................................... 5 
 Secondary objectives  ................................................................................................ 5 
2.3 Study endpoints  ................................................................................................................ 6 
 Primary endpoint  ....................................................................................................... 6 
 Secondary endpoints  ................................................................................................. 6 
 Exploratory endpoints  ............................................................................................... 6 
2.4 Study size and duration  .................................................................................................... 6 
2.5 Study hypothesis  .............................................................................................................. 7 
2.6 Sample size estimation  ..................................................................................................... 7 
2.7 Data analyses  .................................................................................................................... 8 
 Missing data  .............................................................................................................. 8 
2.8 Study population .............................................................................................................. 8 
 Inclusio n criteria  ....................................................................................................... 8 
 Exclusion criteria  ...................................................................................................... 9 
2.9 Concomitant medications  ................................................................................................. 9 
 Prohibited medications .............................................................................................. 9 
2.10  Methods and procedures ................................................................................................. 10 
 Eligibility assessment .............................................................................................. 11 
 Screening visit  ......................................................................................................... 11 
 Baseline  ................................................................................................................... 12 
 Randomization and blinding ................................................................................... 12 
 Procedure (Active and Sham)  ................................................................................. 13 
 30-Day and 90 -day follow -up visits  ....................................................................... 15 
 180-Day, 270- day, and 365- day follow -up visits  ................................................... 15 
 Early withdrawal and lost to follow -up .................................................................. 16 
 End of study  ............................................................................................................ 16 
2.11  Study assessments and data collection  ........................................................................... 17 
 Primary endpoint assessments  ................................................................................ 17 
 Secondary endpoint assessments  ............................................................................ 17 
 Additional assessments  ........................................................................................... 18 
3 Risk/Benefit Analysis  ........................................................................................................... 19 
3.1 Benefits ........................................................................................................................... 19 
Clinical Investigational Plan   Page 2 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  3.2 Potential risks  ................................................................................................................. 19 
3.3 Risk mitigation  ............................................................................................................... 20 
4 Device Infor mation  ............................................................................................................... 20 
4.1 Investigational device description  .................................................................................. 20 
4.2 Investigational device management  ............................................................................... 21 
4.3 Device malfunctions  ....................................................................................................... 21 
5 Monitoring Procedures .......................................................................................................... 21 
5.1 Investigators  ................................................................................................................... 21 
5.2 Investigational center monitoring ................................................................................... 21 
6 Adverse Event Definitions and Reporting ............................................................................ 22 
6.1 Adverse events and serious adverse events  .................................................................... 22 
6.2 Assessing, recording, and reporting of adverse events  .................................................. 22 
7 Protocol Deviations  ............................................................................................................... 23 
8 Labeling  ................................................................................................................................ 24 
9 Administrative Information  .................................................................................................. 24 
9.1 Investigational center selection  ...................................................................................... 24 
9.2 Training .......................................................................................................................... 24 
9.3 Informed consent process  ............................................................................................... 24 
9.4 Confidentiality  ................................................................................................................ 25 
9.5 Institutio nal Review Board (IRB)  .................................................................................. 25 
9.6 Investigator responsibilities ............................................................................................ 25 
9.7 Sponsor responsibilities .................................................................................................. 26 
9.8 Criteria for terminating study  ......................................................................................... 26 
9.9 Criteria for terminating an investigational center  .......................................................... 27 
10 Reports and Records  ............................................................................................................. 27 
10.1  Records  ........................................................................................................................... 27 
10.2  Reporting requirements  .................................................................................................. 27 
11 Publications  ........................................................................................................................... 28 
12 References  ............................................................................................................................. 29 
 
   
Clinical Investigational Plan   Page 3 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  1 Background and Purpose  
1.1 Background  
Rhinitis is a very common condition throughout the world. In the Unites States (US) alone, it 
affects 10 -30% of the adult general population ( 30-60 million people ). The prevalence has been 
increasing in recent decades, making it the 5th most common chronic  disease in the US. Rhinitis 
is the inflammation of the nasal mucosa affecting patients with at least 1 of the following symptoms: nasal congestion, rhinorrhea, sneezing, and nasal itching.   
The current standard of care to control rhinitis  starts with pha rmacologic interventions . Over the 
counter nasal steroids (ie , Flonase, Nasonex) and oral antihistamines (ie , Claritin, Allegra, 
Zyrtec) are the mainstays of medical management. The disadvantages of these medications are that they require daily use and hav e limited effectiveness, especially against nonallergic rhinitis. 
Sedating antihistamines such as Benadryl are used intermittently but the somnolent side effects 
are not usually well tolerated.   
Prescription medications are used when over the counter  medi cation management fails. Oral 
steroids can be effective in the short term but carry more severe long -term side effects , including 
immunosuppression, osteoporosis, Cushing syndrome , and diabetes. Adrenergic agents such as 
Afrin are effective but quickly res ult in tolerance and “rebound” (recurrence and sometimes 
worsening of symptoms when off the medication). 
Surgical treatments are performed w hen pharmacological treatments do not provide an adequate 
response. These treatments  include electrocautery, chemocautery, laser cautery, microdebrider 
turbinoplasty, radiofrequency ablation, subtotal turbinectomy, total inferior turbinectomy, and 
submucosal resection. These procedures primarily seek to address the nasal obstructive component through reduction of the inferior turbinate.  
A variety of  cryosurgical tools for destruction of tissue in the nasal passageway to treat nasal 
obstruction or symptoms of rhinitis have been reported in the literature.
1,2,3,4,5,6,7,8,9,10,11 Target 
nasal passageway locations for cryosurgery have included the nasal soft tissue that cover s the 
turbinates  and include s nasal nerves. All of the studies have included patient -reported outcomes 
(PRO) of nasal symptoms, which is a commonly accepted me thod for demonstrating the 
effectiveness outcomes in the nasal passageway. Physicians also performed visual assessments of 
nasal congestion and recorded the presence of complications including resolution of any adverse 
symptoms. Although published reports reflect improvement in symptoms and a low rate of complications, endoscopic cryotherapy techniques and tools have not been fully optimized to achieve consistent outcomes.  
Arrinex, Inc.  (now part of Stryker ENT) has developed a novel cryotherapy device , the ClariFix 
Cryotherapy device,  designed specifically to facilitate a transnasal approach to allow 
cryoablation of unwanted tissue in the nasal passageway.  
Clinical Investigational Plan   Page 4 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  1.2 Report of prior investigations  
A pilot clinical study was performed at 3 investigational sites in the US to evaluate the 
performance of the ClariFix device as a cryosurgical tool to treat patients  with chronic rhinitis. 
This study was a prospective, multicenter, single -arm interventional , nonsignificant risk study of 
the ClariFix device.  
A total of 27 participants  were enrolled and bilateral treatments were successfully completed 
with no complications in 100% of participants  using injected or topical anesthesia in the office. 
All participants  completed the 30- day follow -up and 24 of the 27 participant s (88.9% ) completed 
the 90- day follow up (3 participants  were lost -to-follow -up) and participated in the extended 
follow -up. Nasal symptoms , assessed by the reflective Total Nasal Symptom Scale ( rTNSS ), 
were significantly reduced at each follow -up interval c ompared with baseline. The average 
rTNSS score was reduced by 58% from 6.2 at baseline to 2.6 at 30 days and the reduction was 
maintained at 2.7 at 90 days (56% reduction). Extended follow -up showed sustained 
improvements : average rTNSS of 2.3 at 180 days post treatment. Eighty -one percent (22/27) of 
participants  had at least a 1- point improvement of rTNSS scores at 30 days and 79% (19/24) of 
participants  had improved rTNSS scores at 90 days. The visual analog scale ( VAS ) scores  
similarly demonstrated significant reductions in nasal symptoms. The average total VAS score 
was reduced by 50% and 53% at 30 and 90 days, respectively. There were no device - or 
procedure -related serious adverse events ( SAEs ) reported during  the study.  This pilot study 
demonstrated that office -based treatment using the ClariFix device was safe, well -tolerated, and 
effective in reducing nasal symptoms in participants  with chronic rhinitis.  
1.3 Purpose  
This study will build on previous results and is designed to demonstrate the superiority of treatment with the ClariFix cryotherapy device compared with a sham procedure in patients with chronic rhinitis. 
2 Protocol  
2.1 Study design  
This is a prospective, multicenter, randomized, sham -controlled, single -blinded study. E ligible 
participants will be randomized 1:1 to active treatment or sham- control . Participants will be 
blinded to their treatment assignment until the 90- day follow -up visit, at which time, the 
participants will be informed of their treatment and sham- control participants will be offered the 
opportunity to crossover to active treatment  if they still meet the inclusion and exclusion criteria . 
Active treatment p articipants and crossover control  participants will be  follow ed through 365 
days after the procedure.  
  
Clinical Investigational Plan   Page 5 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  Figure 1 presents the study design and participant  flow.  
 
2.2 Study objective  
 Primary objective  
To demonstrate that treatment with the ClariFix cryotherapy device is superior to a sham 
treatment in patients  with chronic rhinitis.  
 Secondary objectives  
• To demonstrate durability of the treatment effect through 365 days  of follow -up.  
• To support peer -reviewed publications on the ClariFix technology.  
Sham control procedure  
Randomization  
Exit study  
Crossover?  
No 
30-day visit 
90-day visit (unblinding)  
Yes 
Active treatment procedure  
30-day visit 
180-day visit 
365-day visit 
Exit study  
90-day visit (unblinding, 
initial treatment only)  
270-day visit 
Screening  
Figure 1. Study Design and Participant Flow  Enrollment  Baseline  
Clinical Investigational Plan   Page 6 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  2.3 Study endpoints  
 Primary endpoint  
The primary  endpoint  is the percentage of responders at 90 days . Responders are defined as 
participants with a 30% or greater reductio n in rTNSS  relative to baseline. The active treatment 
group will be compared with the sham -control group.  
 Secondary endpoints  
The following secondary endpoints will compare the active treatment group with the sham -
control group at 30- day and 90- day follow -ups: 
• Mean change from baseline in  rTNSS  score  
• Mean change from baseline in  Standardized  Rhinoconjunctivitis Quality of Life 
Questionnaire (RQLQ(S)) score  
• Mean change from baseline in EuroQol 5- dimension survey ( EQ-5D-5L) scores  
• Percent of patient satisfaction at fo llow-up 
• Rate of s erious device - or procedure -related adverse events  (SAEs)  
The following secondary endpoints will be assessed at all  follow -ups for all participants who 
receive active treatment (randomized or crossover):  
• The percentage of responders  
• The mean change from baseline in rTNSS score  
• The mean change from baseline in RQLQ(S) score 
• Mean change from baseline in EQ -5D-5L scores  
• Percent of patient satisfaction at follow -up 
 Exploratory endpoints  
Additional exploratory outcomes will be detailed in the Statistical Analysis Plan.  
2.4 Study size and duration  
The study will be conducted at up to 12 investigational centers in the US.  
A sufficient number of participants will be screened and consented to reach a total enrollment of  
128 participants. Enrollment in the study is anticipated to take approximately 12 months. 
Participants are considered enrolled at the time of randomization a nd procedure.  
The expected duration of s tudy participation is 13 months for active treatment participants and 
16 months  for sham -control participants who chose to crossover to active treatment . There is a 
maximum of a  30-day screening period for all participants. Postprocedure follow -up for active 
treatment  participant s is 365 days (12 months) . Sham -control participants  who meet the criteria 
may crossover to active treatment after  their 90-day follow -up and then complete the same full 
365-day postprocedure follow -up as the active participants . Those sham -control participants who 
Clinical Investigational Plan   Page 7 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  do not meet the original inclusion/exclusion criteria at the 90- day follow -up or elect not to 
crossover to the active treatment will be exited from the study after their  90-day follow -up. 
2.5 Study hypothesis  
The primary endpoint is the percentage of participants in each arm who achieve an improvement 
≥30% in total  rTNSS  score at  90 days  compared with baseline. The primary endpoint will be 
compared between treatment groups for superiority of active to sham treatment by testing the 
following 1- sided hypotheses using the Z-test of 2 proportions : 
H0: pClariF ix ≤ p sham 
versus  
HA: pClariFix  > p sham 
where p ClariFix  and p sham  are the percentages of responders in the active ClariFix and sham groups, 
respectively.  
2.6 Sample size estimation  
The sample size was calculated using PASS 16 Power Analysis and Sample Size Software (2018) , NCSS, LLC. , Kaysville, Utah, USA ( ncss.com/software/pass ). The sample size was 
calculated  with 90% power and a 2.5% 1- sided type 1 error rate based on the following 
assumptions:  
• 1:1 randomization allocation 
• Percent of rTNSS  responders in active treatment  group = 73.5%  (95% CI, 63.6% to 
81.9%)  
• Percent of rTNSS responders  in sham control group = 45%  
The active response rate is based on the 90 -day response rate in FROST.
12 The sham control 
group rate is based on the placebo rate reported by Benninger et al for a systematic review of 
rhinitis pharmaceutical studies.13 In the drug trials evaluated, they reported  mean placebo 
reponse rates  of –15.0% (range –7.6% to –40.0%) at 2- week follow -up for seasonal allergic 
rhinitis and –24.8% (range –14.4%  to –37.2%)  at 4- to 6- week follow -up for perennial allergic 
rhinitis. To ensure adequate sample size, the anticipated placebo rate was slightly overestimated from these values.  
Additio nally, powering the sample size for subgroup analysis of allergic vs nonallergic 
participant rTNSS responses was considered. However, data from the FROST study  (Table 1)
12 
indicated that there is no difference in response rates between allergic and nonallergic patients 
and that the groups are poolable at the 90- day follow -up period, so enrollment by allergy 
subgroup was not incorporated into the sample size calculation. An assessment of poolability by  
allergy subgroup will be performed during analysis. 
Table 1. FROST 90- Day Total rTNSS Responder Rate  by Allergy Subgroups  
Group  Improved ≥30%  
Allergic  73.3% (22/30)  
Nonallergic  73.5% (50/68)  
Clinical Investigational Plan   Page 8 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  Under the assumptions outlined above, a total sample size of 122 randomized participant s (61 
per arm) is adequate to test this hypothesis. To account for approximately  5% attrition  at 90 days , 
a total of 128 participant s will be enrolled in the study.  
2.7 Data a nalyses  
Summary statistics will be calculated for all study endpoints . Categorical variables will be 
summarized using frequency distributions and continuous variables will be summarized with 
means  and standard deviations  (normal distributions)  or medians and ranges (non- normal 
distributions) . Confidence intervals (95%  CI) may be computed for select study endpoint 
measures. The primary efficacy endpoint will be tested at a 1- sided  alpha level of 0.025 using a 
Chi-square  test. The secondary endpoint s will be tested at a 2- sided  alpha level of 0.05.  
Participant s who are randomized but  drop out before receiving their randomized treatment 
(active treatment or sham procedure) will not be considered enrolled in the study . Participants 
who are unblinded b efore the 90- day visit due to medical necessity will not be included in the 
analysis  of efficacy endpoints . For long- term follow -up analyses, crossover participants will be 
analyzed with the active treatment participants . 
 Missing data  
Missing data can impact the integrity and credibility of any clinical study. Therefore, all attempts will be made to minimize missing data. These attempts include training of the investigators and site personnel and discussions with the participant s during  the informed consent process on the 
importance of accurate and complete data collection. The study sponsor will track issues with sites regarding missing data through the usual monitoring process .  
2.8 Study population  
The study population is comprised of adu lts with chronic rhinitis . To be eligible for enrollment in 
the study the patient s must meet all the inclusion criteria and none of the exclusion criteria.  
 Inclusion criteria 
Study  participant s MUST  meet all of the following criteria : 
1. Be ≥ 21 years of age . 
2. Has been diagnosed with chronic nonallergic or allergic rhinitis . 
3. Have moderate to severe symptoms of rhinorrhea (individual rTNSS symptom rating of 2 or 3), mild to severe symptoms of nasal congestion (individual rTNSS symptom rating of 
1, 2, or 3), and a minimum total rTNSS score of 4 (out of 12) at baseline.  
4. Have an allergy test (by skin prick or intradermal testing or by validated in vitro  tests for 
specific Immunoglobin E [ IgE]) on file within 12 months  of the baseli ne visit.  
5. Be an appropriate candidate for bilateral ClariFix treatment performed under local anesthesia.  
6. Be willing and able to comply with all study elements, as indicated by their written 
informed consent . 
Clinical Investigational Plan   Page 9 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  
 Exclusion criteria  
Study  participants MUST NOT  meet any of the following criteria : 
1. Have clinically significant anatomic obstructions that, in the investigator’s opinion, limit 
access to the posterior nose, including but not limited to severe septal deviation or perforation, nasal  polyps, and/or sinonasal tumor . 
2. Have had previous sinus or nasal surgery within 6 months of study enrollment . 
3. Have previously undergone cryotherapy or other surgical interventions for rhinitis.  
4. Have an active nasal or sinus infection . 
5. Have rhinitis sympto ms that are primarily due to seasonal allergies . 
6. Have plan s to (or otherwise anticipate s the need to)  undergo an ENT procedure 
concurrently or within 3 months after  the study procedure.  
7. Is on prescribed anticoagulants (eg, warfarin, Plavix) or 325 mg aspir in that cannot be 
discontinued before the procedure (81 mg aspirin and herbal supplements are acceptable).  
8. Be unable to discontinue ipratropium bromide ( IB) at least  14 days before baseline 
and 
through the 90- day follow -up visit . 
9. Have a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis event requiring medical intervention ) in the past 3 months . 
10. Have a history of rhinitis medicamentosa . 
11. Have had previous head and/or neck irradiation . 
12. Have an allergy or intolerance to local  anesthetic agent s. 
13. Have cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud’s disease, and/or open and/or infected wounds at or near the target tissue . 
14. Have a neurological, medical,  psychiatric condition, or social circumstance that would 
potentially increase risk, interfere with study participation, or confound interpretation of study data  
15. Be participating in another clinical research study . 
2.9 Concomitant medications  
Concomitant m edication s that should be documented at screening  and throughout the study  
include  the following : 
• Medications taken for rhinitis, allergies, asthma, sinusitis, migraines, and  GERD (or any 
other ENT, head and neck, respiratory, and/or airway related conditions or systems ), 
including saline .  
• Medications administered to treat a study -related adverse event. 
Additionally, any m edication, as deemed by the investigator, to present a potential safety risk at 
the time of the procedure ( eg, beta -blockers)  should be note d as a concomitant  medication .  
 Prohibited medications  
Any p articipants taking nasal anticholinergic sprays (eg, IB) will be instructed  at screening  to 
discontinue  use at least 14  days before the baseline visit and through the 90 -day follow -up visit . 
Clinical Investigational Plan   Page 10 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  Participants will also be instructed not to c hang e their baseline concomitant medications 
(start/stop or change of dose) before the 90 -day study follow -up, unless required to treat an 
adverse event.  
2.10 Methods and p rocedures  
Study methods and procedures are described below. A n overview of the required study 
assessments at each follow -up visit is provided in Table 2. Each participant’s follow -up schedule 
is based on the procedure date. Control participants who elect crossover after the 90- day visit 
will undergo a ClariFix procedure  and then continue follow -up through 365 days  after the active 
treatment . 
Table 2. Study Assessment Schedule  
Study evaluation  Study Visit (window)  Screening ( up to 30 
days preprocedure)a 
Baseline  (up to 7 days 
preprocedure)b 
Randomization  & 
procedure (day 0)b,c 
30-Day (± 7 days) c 
90-Day (± 14 days) c 
180-Day (± 21 days)c 
270-Day (± 21 days)c 
365-Day (± 21 days)c 
Informed consent          
Demographics and medical history          
Clinical evaluation          
Eligibility assessment          
Urine p regnancy testd         
Randomize to treatment arm          
Procedure  (active or sham)          
Record procedure information          
Blinding questionnairee         
Adverse events          
Concomitant medicationsf         
Quantitative endoscopic rhinoscopyg         
rTNSS          
RQLQ(S)          
EQ-5D-5L         
NOSE          
Participant satisfaction          
a The procedure must take place within 30 day of the screening visit.  
b The participant must discontinue use of IB at least 14 days  before the baseline visit . The procedure must be scheduled within 7 days of 
the baseline visit (it can be the same day as baseline if all criteria are met).  
c  Control participants electing to crossover to active treatment will undergo a ClariFix procedure and then continue follow -up through 365 
days  after the active treatment . 
d Urine pregnancy tests are required for all women of childbearing potential before the  procedure.  
e Blinding questionnaire is only completed for the initial randomized treatment procedure (active or control), not for crossover treatments.  
Clinical Investigational Plan   Page 11 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  Study evaluation  Study Visit (window)  Screening ( up to 30 
days preprocedure)a 
Baseline  (up to 7 days 
preprocedure)b 
Randomization  & 
procedure (day 0)b,c 
30-Day (± 7 days) c 
90-Day (± 14 days) c 
180-Day (± 21 days)c 
270-Day (± 21 days)c 
365-Day (± 21 days)c 
f Concomitant m edications include those taken for rhinitis, allergies, asthma, sinusitis, migraines,  and GERD (or any other ENT, head 
and neck, respiratory, and/or airway related conditions or systems ), including saline; and medications taken to treat a study -related 
adverse event . Additionally,  any medications deemed to present a potential safety risk at the time of the procedure (eg, beta- blockers) 
should be documented.  
g Quanti tative endoscopic rhinoscopy will consist of an assessment of nasal congestion before administration of decongestant and an 
assessment to include rhinorrhea and nasal congestion after administration of a decongestant.  
 
 Eligibility assessment  
Patients are considered eligible for this study if they meet all  the inclusion criteria and none  of 
the exclusion criteria as defin ed in Section 2.8. The principal investigator or s ubinvestigator at 
each investigational center will determine patient eligibility based on the inclusion/exclusion 
criteria.  Participants will be considered enrolled at the time of randomization and procedure.  
 Screening visit 
The initial screening visit can occur up to 30 days before the study procedure.  
For individuals who  have been prescreened f or eligibility, the following procedures/assessments 
will be performed  at the screening visit : 
1. Informed consent form signed . 
2. Participant  completes  the rTNSS questionnaire . 
3. Record demographics and patient medical and surgical history  (with focus on 
nasopharyngeal, ocular, and respiratory  conditions ; allergies ; and rhinitis history) . 
4. Record concomitant medications ( See Section 2.9 ). 
5. Clinical evaluation , including visual inspection of eyes, mouth/throat, and ears  to confirm 
participant’s overall health and suitability to undergo the study procedure . 
6. Perform a q uantitative endoscopic rhinoscopy  before administration of nasal decongestant 
to evaluate nasal congestion . 
7. Administer nasal decongestant . If the participant is a woman of childbearing potential , use 
medical judgement to select a decongestant  (eg, oxymetazoline)  that is safe to use during 
pregnancy.  
8. Repeat quantitative endoscopic rhinoscopy to evaluate nasal structures, treatment site, and assess degree/extent of rhinorrhea and postdecongestant nasal congestion . 
Clinical Investigational Plan   Page 12 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  9. Determine  if an allergy test conducted within 12 months  is available  and whether 
participant ’s rhinitis is allergic or nonallergic. If an allergy test is not on file, a blood 
allergy test  (IgE level)  should be scheduled to take place before  the baseline visit.  
10. Review of study eligibility criteria . 
Patients  not meeting the screening criteria will be considered screen failure s and are not eligible 
for participation in  the study.  
Participants  continuing in the study will be scheduled for the b aseline visit. For p articipants 
using IB , they must discontinue IB  usage at least 14  days before the baseline visit.  
 Baseline  visit 
The following activities are conducted  at the baseline visit:  
1. Participant completes questionnaires: rTNSS, RQLQ( S), EQ -5D-5L, and Nasal 
Obstruction Symptom Evaluation (NOSE) .  
2. Record concomitant medications  (confirm discontinuation of IB for at least 14 days prior, 
if applicable) . 
3. Review eligibility criteria; if participant  continues to meet eligibility  criteria , schedule for  
randomization and procedure. The study procedure must  be scheduled within 7 days of the 
baseline visit ( the procedure can occur on  the same day as the b aseline visit if all criteria 
are met) . 
 Randomization  and blinding  
Randomization assignments will be generated by in independent statisitician using variable 
block size distribution by site with a 1:1 allocation to active or sham treatment. Randomization 
will also be stratified by allergy subgroup (allergic, nonallergic). The randomization schedule 
will be entered int o the M edrio  electronic data collection ( EDC ) randomization module . 
Randomization will occur on the day of the procedure and after all baseline data have been 
collected and eligibility has been confirmed. All randomized and treated participants  will be 
considered enrolled.  Confirmation of randomization assignment from EDC will be printed and 
filed in the study record.  
This is a single -blind study; p articipants will be blinded to the randomized assignment. To 
facilitate b linding, control participants will undergo  a sham procedure using the ClariFix device 
without a cryo gen cannister . To support blinding, participants will wear blindfolds during the 
procedure to limit any visual clues that may suggest the treatment assignment.  A separate 
device with a canister held near the participant will be used to provide  the sound of the gas 
release from the cannister. A standardized script for the physician/staff will be used during the 
procedure to assure blinding. Additionally, local anesthesia regimes will be the same for both 
treatment groups within each investigational center.  
Participants will complete a blinding questionnaire at completion of the procedure and at the 
30-day and 90 -day follow -up visits  to asses s the adequacy of the blinding procedures . Upon  
Clinical Investigational Plan   Page 13 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  completion of the ir 90-day visit, each  participant will be unblinded . Sham control participants 
will be offered the opportunity to receive active treatment if they wish and still meet eligibility 
criteria .  
Before the 90 -day visit, unblinding of participants will only occur when medically necessary. In 
the event of a device -or procedure -related S AE, the  sponsor may authorize the site to unblind 
the participant in order to adequately assess the even t. 
 Procedure (Active and Sham) 
Pregnancy testing  
Before the procedure, urine pregnancy tests are required for all women of childbearing potential. 
In the case of pregnancy, use medical judgement  to select appropriate procedural anesthesia 
medications (eg, low doses of epinephrine and lidocaine) that are safe for use during pregnancy . 
Procedure anesthesia  
The local anesthesia regimen for the procedure for both active and sham treatments will be performed according to the physician’s usual practice. Information regarding the anesthesia 
regimen will be documented  in the study records . 
Study procedure  
Below is a high -level description of the procedure for both the active and sham procedures. 
Detailed instructions on the preparation, usage, and storage of the ClariFix device is available in the instructions for use ( packaged with the device ). To maintain the participant blind during the 
procedure, the sham devices will be identical to the active devices except the cryo gen cannister  
will not be inserted into the device .  
1) Review and update concomitant medications. 
2) Perform quantitative endoscopic rhinoscopy  before administratio n of nasal 
decongestant to evaluate nasal congestion.  
3) Administer decongestant.  If the participant is a woman o f childbearing potential, use 
medical judgement to select a decongestant (eg, oxymetazoline) that is safe to use during pregnancy.  
4) Perform quantitative endoscopic rhinoscopy  to assess degree/extent of rhinorrhea and 
postdecongestant nasal congestion, and plan target treatment placement at the middle meatus.  
5) Administer  local anesthesia to both sides of the nasal cavity . 
6) Have the participant put on the blindfold. 
7) Prepare the Cl ariFix device ac cording to the IFU (for sham treatment, do not insert the 
cryogen cannister ). 
8) Place the cryoprobe in firm contact with the target ed middle meatus  tissue under visual 
guidance.  
Clinical Investigational Plan   Page 14 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  9) For active treatment:  initiate  the flow of cr yogen  for a total of 30 seconds  and, using 
endoscopic visualization, ensure the cryoprobe is functioning .  
For sham treatment : turn on the device and leave the cryoprobe in contact with tissue 
for the 30 seconds, tissue will  not freeze with the  sham treatment . Use a separate device 
held near the participant to provide the sound of gas release from the cannister.  
For both treatments, d uring this time, instruct the participant breathe in and out 
through their mouth.  
10) After the treatment (active or sham) wait at le ast 60 seconds before removing the 
cryoprobe  to allow  the cryoprobe to release from the target tissue (active). During this 
time, instruct  the participant  to breathe in through their mouth and out through 
their nose.  
11) Remove the device from the target tiss ue. 
12) At the physician’s discretion, steps 8 through 11 above may be repeated for a second 
treatment of up to  30 seconds  on the same side . 
13) Repeat  steps 8 to 12 above for treatment on the contralateral side.  
The following data will be collected during the study procedure  and documented i n the 
appropriate study records : 
• Type of anesthesia, including  method of administration, location , and dosage  
• Individual freeze (or sham) cycle  
• Procedure  durations  (including time roomed, anesthesia start, procedure start, procedure 
stop, leaves procedure room /treatment chair , discharge)  
• Adverse events  
• Active or sham treatment  
• Device m alfunctions  
Postprocedure care  
Participant  will be monitored at the clinic for a minimum of 30 minutes after the procedure. 
During this time, have the participant  complete the blinding questionnaire  (for initial 
randomized treatment only  – active or control ). 
During the postprocedure waiting period, participants will be a sked to rate their postprocedure 
pain/discomfort on a scale of 0 (no pain/discomfort) to 10 (severe pain/discomfort). Any report 
of severe pain /discomfort  (≥7) during the postprocedure waiting period shall be reported as an 
adverse event.  Anesthesia (eg , lidocaine, marcaine) may be injected at the treatment site to 
alleviate or minimize participant pain.  
Postprocedure n asal saline rinses  or sprays may be prescribed, as needed, or in accordance with 
the physician’s standard practice.  
Concomitant procedures  
Concomitant procedures are not allowed in this study. No additional sinonasal procedures s hould 
be scheduled within 3 months after the index procedure.  
Clinical Investigational Plan   Page 15 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  At the physician’s discretion, after the 90- day postprocedure visit, ClariFix r etreatment or other 
surgical interventions for rhinitis may be performed for participants who experience continuing 
or recurrent symptoms. Such treatments will be documented in the study records . The 
participants will continue to be followed according to their initial follow -up schedule.  
 30-Day and 90-day follow -up visit s 
All randomized and treated  participant s will attend the following postprocedure  study visits  
(window) : 
• 30-Day in-office visit (± 7 days)  
• 90-Day in-office visit (± 14 days) ; all participants will be unblinded to treatment 
assignment  at this visit 
The following assessments are required at these follow -up visits (also see Table 2):  
1. Patient -reported questionnaires: rTNSS, RQLQ(S), EQ -5D-5L, NOSE, and satisfaction  
2. Review and update  concomitant medications  
3. Review and update  adverse events  
4. Perform quantitative endoscopic rhinoscopy  before administration of nasal decongestant 
to evaluate nasal congestion  
5. Administer decongestant and perform quantitative endoscopic rhinoscopy  to evaluate 
treatment site, and assess degree/extent of rhinorrhea and postdecongestant nasal congestion. If th e participant is a woman of childbearing potential, use medical judgement 
to select a decongestant (eg, oxymetazoline) that is safe to use during pregnancy.  
6. Blinding questionnaire  (only for initial randomized treatment – active or control ) 
Control particip ants who elect to undergo crossover to active treatment after their 90- day visit 
will repeat these visits after the active treatment procedure. All activities for these visits are 
repeated and documented except for  the blinding questionnaire, which is no l onger applicable.  
 180- Day, 270-day, and 365 -day follow -up visit s 
All participants who receive active treatment (as randomized or crossover  participants ) will 
continue with the following long -term visits  (window):  
• 180-Day visit ( ±21 days)  
• 270-Day visit (±21  days)  
• 365-Day visit (±21 days)  
The following assessments are required  at these long -term follow -up visits  (also see Table 2) : 
1. Patient -reported questionnaires: rTNSS, RQLQ(S ), EQ -5D-5L, NOSE, and satisfaction  
2. Review and update  concomitant medications  
3. Review and update  adverse events  
4. Perform quantitative endoscopic  rhinoscopy  before administration of nasal decongestant 
to evaluate nasal congestion  
Clinical Investigational Plan   Page 16 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  5. Administer decongestant and perform quantitative endoscopic rhinoscopy  to evaluate 
treatment site, and assess degree/extent of rhinorrhea and postdecongestant nasal 
conges tion. If the participant is a woman of childbearing potential, use medical judgement 
to select a decongestant (eg, oxymetazoline) that is safe to use during pregnancy.  
The study is complete for each participant upon completion of their 365- day follow -up. 
 Early withdrawal and lost to follow -up 
Study participant s are free to withdraw from the investigation at any time without having to 
justify their reasons and without affecting their  relationship with the i nvestigator. An i nvestigator 
may also withdraw a participant  from the study at any time if it is determined  to be in the 
participant ’s best interests.  
A participant ’s future management will not be changed by a decision, voluntary or otherwise, to 
withdraw from the study. All reasonable efforts should be made to retain participants until completion of the clinic al study. Reasons for termination or withdrawal include but are not 
limited to the following: 
• Participant  death  
• Participant  request  
• Participant  lost to follow -up. A participant  is considered “lost to follow -up” after a 
minimum of 3 documented attempts to r each the participant . The last attempt must be by 
a traceable method (eg, read- receipt email, certified letter)  
• Participant ’s participation terminated by the i nvestigator  
• Study terminated by the s ponsor  
For any participant s with early withdrawal or termination, termination information will be 
recorded in the participant’s records and the date of last contact with the participant  noted in the 
study records . 
 End of study  
Participant s randomized to the control arm who do not c rossover to active  treatment are exited 
upon completion of the ir 90-day visit. For all other treated participa nts, the study is considered 
complete upon completion of the 365- day postprocedure visit.  
If a participant  has a ClariFix  device inserted into their nose  but does not undergo either an 
active or sham treatment, the participant  will be contacted  by phone approximately  30 days  after 
the procedure to inquire about adverse events  (AEs).  If the participant has not experienced any  
device or procedure- related AEs , they can  then be exited f rom the study . If the participant  has an 
ongoing device or procedure -related AE , they will be followed until AE resolution or 90 days  
after the procedure, whichever  comes first.  
Study exit will be documented in the study records  when the participant  has completed their last 
required follow -up visit  or at the time of withdrawal or lost to follow -up, if the participant  
discontinues the study prematurely . 
Clinical Investigational Plan   Page 17 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  2.11 Study assessments and d ata collection  
Study data will be collected according to Good Clinical Practices . Source worksheets  will be 
provided to the investigational sites for collection of study data. Data will be entered into the 
study database by investigational site staff using the Medrio EDC syste m. The data will be 
reviewed by Stryker ENT  staff , or designee,  and any queries will be  submitted to the 
investigational center  for clarification. Patient -reported outcome questionnaires may be entered 
into the EDC directly by study participants  or entered by study staff from paper source 
documents . 
The required study assessments for each specified interval are outlined in the Section s 2.10.6 and 
2.10.7. See Table 2 for an overview of the required study assessments at ea ch follow -up visit. 
Each participant ’s follow -up schedule is based on the date of their study procedure . 
 Primary endpoint assessments  
Reflective Total Nasal Symptom Score (rTNSS)  
The reflective Total Nasal Symptom Score (rTNSS ) is a validated patient -reported outcome 
(PRO) used to descri be symptoms of rhinitis.14 The assessment consists  of 4 nasal symptom 
domains (runny nose  [rhinorrhea] , itchy nose, sneezing, and stuffiness [ nasal congestion ]). Each 
item is rated  from 0 ( absent ) to 3 (severe ). The 4 domains are added together to provide an 
overall score ranging from 0 to 12. 
The primary efficacy endpoint is the comparison of active vs sham -control groups for the percent 
of responders  at the 90- day follow -up. A responder is defined as a participa nt having a 30% or 
greater  reduction in total rTNSS compared with baseline. 
 Secondary endpoint assessments  
Reflective Total Nasal Symptom Score (rTNSS)  
The rTNSS will be collected a t screening, baseline, and all follow -up visits. The mean change 
from baseline in the  rTNSS for both treatment groups will be evaluated and compared between 
treatment groups as a secondary endpoint at the 30 -day and 90- day follow -up periods. 
Additionally, t he mean change from baseline will be accessed at all  follow -ups for all 
participants who received active treatment (randomized or crossover).  
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ (S)) 
The RQLQ (S) is a validated PRO that  measures  functional impairments due to allergic or non -
allergic rhinoconjunctivitis.15,16 The assessment consists of 28 questions related to nose  
symptoms, eye symptoms, non- eye/nose symptoms, sleep problems , practical problems, activity 
limitations , and emotional function. Each item is scored from 0 (no impairment) to 6 (severely 
impaired). An overall score is calculated from t he mean of the 28 item responses. Domain scores 
are the mean of the item scores within that domain. The RQLQ(S) differs from the initial RQLQ 
in tha t it standardizes the 3 activities reported for the duration of the study.  
Clinical Investigational Plan   Page 18 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  The RQLQ(S) will be completed at baseline and all follow -up visits.  The mean change from 
baseline in the RQLQ(S) will be evaluated and compared between treatment groups as a 
second ary endpoint at the 30- day and 90-day follow -up periods. Additionally, the mean change 
from baseline will be accessed at all  follow -ups for all participants who received active treatment 
(randomized or crossover).  
EuroQOL (EQ- 5D-5L) 
The EQ -5D-5L is a vali dated, standardized questionnaire used to evaluate general health -related 
quality of life.17,18 The questionnaire consists of 5 health dimension s (mobility, self -care, usual 
activities, pain/discomfort, and anxiety/depression) and a visual analog scale (VAS)  to indicate 
overall health on a scale of 0 to 100. Each health dimension has 5 possible responses: no 
problems, slight problems, moderate problems, severe problems, or extreme problems. The 
questionnaire is designed to be self -completed by the participant .  
The EQ -5D-5L will be completed at baseline and all follow -up visits.  The mean change from 
baseline in the EQ -5D-5L will be evaluated and compared between treatment groups  as a 
secondary endpoint at the 30- day and 90-day follow -up periods. Additionally, the mean change 
from baseline will be accessed at all  follow -ups for all participants who received active treatment 
(randomized or crossover). 
Satisfaction questionnaire  
The satisfaction questionnaire consists of 3 questions that the participant answers at each follow -
up visit. The questions indicate whether the participant is satisfied with the procedure outcome, 
whether the participant would undergo the procedure again for similar results, and whether the participant woul d recommend the procedure to family or friends with a similar condition. For 
each item the participant indicates agreement/disagreement with each statement.  
Serious device - or procedure -related a dverse events  (SAEs)  
The rate of serious device - or procedure -related adverse events  (SAEs) will be compared 
between treatment groups through the 90 -day follow -up visit  (Section 6) . The parameter of 
interest is the percent of participants who experience 1 or more device - and/or procedure -related 
SAEs  from the time of the index procedure through the 90- day follow -up. 
 Additional assessments  
Blinding questionnaire  
The blinding questionnaire is intended to assess the adequacy of participant blinding . 
Participants are asked to indicate which study arm (active or sham) they believe they were assigned to, the reasons for their belief, and other questions to assess the overall treatment experience. The blinding questionnaire will be completed immediately post procedure and at follow -up visits through 90 days  from the initial randomized treatment only  (active or sham) . 
  
Clinical Investigational Plan   Page 19 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  Nasal Obstruction Symptom Evaluation (NOSE)  questionnaire  
The NOSE scale is a standardized, validated PRO that evaluates the patient’s perception of their 
ability to breathe through their nose.19 Patient’s r ate to 5 items (nasal congestion or stuffiness, 
nasal blockage or obstruction, trouble breathing through the nose, trouble sleeping, and unable to 
get enough air through the nose during exercise or exertion)  on a scale of 0 (not a problem) to 4 
(severe problem). The sum of the items is multiplied by  5 to provide an overall score with a 
possible range of 0 to 100, with higher s cores indicating worse symptoms. This is an exploratory 
outcome measure.  
3 Risk/Benefit Analysis  
3.1 Benefits  
Participation in this study is voluntary . Participant s with rhinitis may experience an improvement 
in their symptoms.  
3.2 Potential risks  
Study participant s will be informed of all known potential side effects and complications 
associated with study treatment and study assessments before consenting for  the study. The risks 
associated with participating in the study are the same as those that the participant  would have if 
treated with nasal cryotherapy  outside of the study.   
While endoscopic rhinos copy is generally known to be safe, anticipated risks may include, but 
are not limited to: 
• Temporary pain, discomfort or irritation  
• Bleeding  
• Cerebrospinal  fluid (CSF) leak  
Similarly, while generally known to be safe, submucosal placement of a needle and delivery of 
local anesthesia may be additionally associated with the following risks, not limited to:  
• Minor bleeding  • Visual disturbance  
• Pain with injection  • Vomiting  
• Facial numbness or tingling  • Headache  
• Sedation  • Tinnitus  
• Tachycardia, nervousness, anxiety  • Seizures  
• Lightheadedness, dizziness, confusion  • Hypotension, bradycardia  
• Muscular twitching, tremors  • Unconsciousness  
• Infection  • Respiratory arrest  
• Allergic reaction  • Cardiac arrest  
• Lidocaine or tetracaine toxicity with overdose  
Clinical Investigational Plan   Page 20 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  In addition, the specific nature of cryosurgery using the ClariFix device results in a known 
potential for adverse events related to the cold application, including but not limited to:  
• Bleeding  • Headache  
• Crusting and/or tissue sloughing  • Dry nose  
• Swelling  • Ear blockage  
• Pain/discomfort and/or facial pain  • Septal perforation  
• Increase in nasal congestion  • Vasovagal reaction  
• Intranasal scarring/nasal obstruction  • Infection  
• Sensory alterations (numbness, tingling) in 
the face/mouth  • Dry eyes, optical changes 
or orbital damage  
Also refer to  the manufacturer’s Instructions for Use (IFU)  provided with the device . 
There is also a possible ris k of a loss of confidentiality. The sponsor will take all reasonable 
efforts to prevent the release of confidential participant information in accordance with the local and national privacy laws. 
3.3 Risk mitigation  
The protocol has been developed to minimize  the risks for the participant  in a number of ways. 
Sample size was calculated to expose the smallest number of participant s while still being able to 
adequately test the study hypothesis . The procedure will be performed by practicing 
otolaryngologists experienced in transnasal procedures  and trained on the use of the ClariFix 
device. Investigators are expected to comply with the manufacturer’s IFU for the ClariFix 
device. The participant  selection criteria have been  designed to minimize risk by excluding 
patients who have comorbidities or conditions that may put the patient at higher risk for cryotherapy . Specifically, patients  with known allergies to local anesthetic agents are excluded 
from participation in the s tudy. Women of childbearing potential will be required to take a urine 
pregnancy test before the  procedure to allow for appropriate selection of procedure anesthesia 
medications that are safe to use during pregnancy. Concomitant procedures that could increa se 
risk and confound study results are not permitted during the study. Finally, t he participant s will 
be closely monitored by frequent follow -up visits during the study.  
4 Device Information  
4.1 Investigational device description  
The study device is the ClariFix® Cryotherapy device ( ClariFix ). The  device  is currently a Class 
I, 510(k) -cleared, commercially available device for chronic rhinitis . Use in this study is on- label 
with the cleared indications for use.  
The ClariFix device is a handheld, single p atient -use, disposable cryosurgical device used for the 
destruction of tissue during surgical procedures. The device consists of a handle attached to a 
Clinical Investigational Plan   Page 21 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  cannula with a cryoprobe at the distal end. The ClariFix device is provided sterile to the user. See 
the IFU packaged with the device for further information . 
4.2 Investigational device management  
ClariFix devices will be provided to the investigational centers specifically labeled “for study use  
only” . Active and sham devices will be identical. The cryo gen cannister will not be inserted in 
the device for the sham procedures.  
The sponsor will monitor use of the study  devices by the following activities: 
• Shipping or hand- carrying devices  only to approved investigators who are participating in 
the study  
• Maintaining records of shipment and distribution of the devices  
• Maintaining records of devices used on participant s and returned devices  
4.3 Device malfunctions  
A device malfunction is defined as a failure of a device to meet its performance specifications or 
otherwise to perform as intended. A malfunction may be a result of any of the following:  failure , 
malfunction , improper or inadequate design , manufacturing , labeling , or user error . 
All device malfunctions must  be reported  to the sponsor . All attempts should  be made to return 
malfunctioning device s to Stryker ENT  for evaluation. Contact the clinical monitor for 
instructions on used device preparation and return procedures.  
5 Monitoring Procedures  
Stryker ENT  personnel or qualified designees will monitor the clinical study  in a manner 
consistent with 21 CFR 812, Subpart C, Responsibilities of Sponsor. C ontact information will be 
provided separately.  
5.1 Investigators  
The clinical monitor s will ensure investigators are selected based on t heir qualifications and 
ability to fulfill the investigator responsibilities  as outlined in Section 9.6. 
The Lead Investigator for the study is Dr. Anthony DelSignore  of the Icahn School of Medicine, 
Mount Sinai, New York, NY . 
5.2 Investigational center monitoring  
A risk -based approach to monitoring of the study will be utilized and outlined in a Clinical 
Monitoring Plan. Monitoring visits to the investigational centers will be conducted at a frequency sufficient  to ensure that all aspects of the current approved protocol and any amendment(s) are 
followed. Source documents will be reviewed for verification with data in the e CRFs and all 
regulatory documents will be checked for accuracy including but not limited to IRB approvals, 
Clinical Investigational Plan   Page 22 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  study -related correspondence, and participant  informed consent. The i nvestigator and/or 
investigational center staff must be available to m eet with the s ponsor during monitoring visits.  
Upon reasonable notice, t he investigator and i nstitution agree to provide the  sponsor 
representatives or designees and applicable regulatory authorities with direct access to source 
documents  relevant to the study for s ponsor quality assurance audit s or inspect ions by the 
regulatory authorities.  
6 Adverse Event Definitions and Reporting  
6.1 Adverse events and serious adverse events  
An adverse event (AE) is any undesirable clinical occurrence experienced by the participant during the follow -up period regardless of the event’s relationship to either the study device or 
procedure. An underlying disease that was present at the time of enrollment is not an AE; however, any increase in the severity of an underlying disease is an AE.  
A serious adverse event (SAE) is an event  that results in any of the following:  
• Death  
• Life-threatening  
• Hospitalization or prolongation of an existing hospitalization  
• Invasive surgical intervention to correct or prevent further injury  
• Persistent or significant disability or incapacity  
• An important  medical event  
An important medical event that may not meet one of the above definitions might be considered 
as an SAE if it jeopardizes the health of the participant or requires surgical intervention to 
prevent one of the outcomes listed in the above defi nition.  
An elective hospitalization/intervention that was planned before the participant enrolled in the study is not considered an SAE as defined above.  
6.2 Assessing, recording, and reporting of adverse events  
For the purposes of this study, all  serious adverse events (regardless of relationship) must be 
reported. Only nonserious adverse events that are related to the device, procedure , or the 
participant’s ENT condition(s) should be reported. Nonserious adverse  events that are not related 
to the device, procedure, or ENT conditions should not be reported.  
An adverse event  may be volunteered spontaneously by the participant  or discovered by the 
investigator or study staff upon questioning or physical examination of the participant. The 
following information should be reported for all reportable adverse events and updated as needed 
until the event resolves : 
• Adverse event (diagnosis associated with the main complaints or symptoms)  
• Date the adverse event  occurred  
• Date the i nvestigator (or staff) became aware of the adverse event  
Clinical Investigational Plan   Page 23 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  • Adverse event details (m ain complaints  or symptoms ) 
• Relationship to study device  
• Relationship to the study procedure  
• Seriousness of the adverse event  
• Interventions undertaken  
• Status of the adverse event (ongoing, resolved, unresolved but stable, death)  
• Date of event resolution, if applicable  
Source documents (eg , procedural notes, treatment notes,  clinical summary) may be required as 
supporting documentation for an adverse event .  
Any serious device - or procedure -related adverse events should be reported to the sponsor as 
soon as possible (preferably within 24 hours)  after the investigator or clinic staff become aware 
of the event. Initial report of the event can be by email and/or telephone call to a sponsor 
representative.  
During the study , all participant deaths must be reported to the s ponsor within 24 hours  of the 
investigator’s (or designated staff’s) knowledge of the death. Deaths should be reported as the 
reason for study ex it and the  cause of  the death should be reported as an adverse event . A copy of 
death records, medical records for the event (s) that led to the participant ’s death, death certificate 
(if available) , and an autopsy report (if performed) should be deidentifi ed and sent to the s ponsor 
as soon as they become available  for any death deemed related to the device and/or procedure . 
7 Protocol D eviations  
Investigators are required to adhere to the study protocol, applicable national or local laws and 
regulations, and any conditions required by the applicable IRB or regulatory authority.  
A protocol deviation is used to describe situations in which the prot ocol was not followed 
(including all required activities at each scheduled visit or activities occurring outside of the study windows).  
An investigator must notify the sponsor and the applicable IRB of any deviation from the study protocol done to protect  the life or physical well -being of a participant  (medical emergencies). 
Such notice should be given within 24 hours. The sponsor will determine if the participant  
affected is eligible to continue in the study.  
Deviations identified by the investigational center, the monitor, or other sponsor 
representative(s) will be documented in the study records  for tracking compliance with the 
protocol. The investigational centers will be required to document actions taken to prevent recurrence of deviations. The spons or representative may  initiate corrective actions based on 
individual deviations or trending reports, as appropriate.  
Clinical Investigational Plan   Page 24 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  8 Labeling  
An additional sticker will be added to the  existing FDA -cleared labeling (package labels) for the 
ClariFix  device to indicate the  device is “for study use only” .  
9 Administrative Information  
9.1 Investigational center selection  
The study will be conducted at up to 12 investigational centers in the US . Centers will be 
evaluated to ensure each center has the capacity and capability to obtain informed consent and 
comply with all protocol requirements. The i nvestigators and investigational center personnel are 
required to comply with the principles of Good Clinical Practices (GCP) as described in the FDA regulations. 
9.2 Training  
The training of investigational center personnel wil l be the responsibility of the sponsor or 
sponsor -authorized representatives. All treating physicians must be proficient in the use of 
endoscopic techniques. All physicians will be trained on the preparation and use of the ClariFix  
device before participant  enrollment in this study.  
To ensure  unifo rm data collection and protocol compliance, the sponsor or s ponsor -authorized 
representatives will review all components of the study with the study c oordinator(s)/study staff 
at each investigational center. The review will include the study protocol, techniques for the identification of eligible patients, instructions for data collection during the procedure, schedules for follow -up, and training on the EDC system . 
9.3 Informed consent process  
Informed consent must be obtained in accordance with US regulation 21 CFR 50. The 
participant s must be informed about their right to withdraw from the study at any time and for 
any reason without sanction, penalty, or loss of benefits to which the participant  is otherwise 
entitled and also informed that withdrawal from th e study will not jeopardize their future medical 
care. The standard institutional patient consent form does not replace the study informed consent 
form (ICF).  
The s ponsor will provide  a study -specific ICF  template  to the central IRB and to  each 
investigational center  under jurisdiction of a local IRB . For sites under the jurisdiction of a local 
IRB, t he template may be modified to suit the requirements of the individual investigational 
center ; however, t he sponsor must preapprove all changes to the ICF  befo re initial submission to 
the IRB. The IRB -approved consent form  must be sent to and approved by the s ponsor before the 
first device shipment . All investigational centers must retain  one copy of the IRB -approved ICF  
in the study files  along with the other inve stigational forms.  
Each enrolled participant  must be given a copy of the ir signed consent form  and the original  
Clinical Investigational Plan   Page 25 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  must be retained in the investig ational center study file for that participant . A copy may also be 
sent to medical re cords, if required by institutional policy. Informed consent documents must be 
available for review by the s ponsor during monitoring visits. 
Modifications to the study -specific ICF and/or any other written information distributed to 
participant s must be pr eapprove d by the s ponsor  and the IRB , as necessary.  
9.4 Confidentiality  
All in formation and data sent to the s ponsor concerning participant s or their participation in this 
study will be considered confidential. Participant s will be identified by a study -specif ic 
identification code. All data used in the analysis and reporting of this investigation  will use the 
study -specific codes and will not include identifiable references to individual  participant s. Any 
source documentation must be deidentified by the investigational center befo re being sent to the 
sponsor.  
The i nvestigator will allow  visits by the s ponsor representatives and the US FDA inspectors or 
any other local governmental body to review the study participant s’ medical records.  
9.5 Institutional Revi ew Board (IRB)  
It is the investigator’s responsibility to obtain and maintain written approval of the final 
investigational plan  and ICF from the applicable  IRB. The i nvestigator is  responsible for 
submitting and obtaining initial and continuing review of the study by the  IRB. It is also the 
investigator’s responsibility to notify the IRB of any amendments to these documents. Written 
IRB approval must identify the study by title and version, document the date of review, and be 
forwarded to the s ponsor befor e the first device shipment.  
The i nvestigator  must keep all study -related correspondence with the IRB on file and forward 
copies of such correspondence to the s ponsor.  
It is anticipated that the c entral IRB listed below will be used for most, if not all, investigational 
sites. The sponsor may help fa cilitate submissions to the central IRB on behalf of the 
investigators.  
Advarra IRB  
6940 Columbia Gateway Dr. Suite 110 Columbia, MD 21046 
9.6 Investigator responsibilities  
The i nvestigator for each investigational center  is responsible for ensuring the study is conducted 
according to:  
• All signed agreements  
• The s tudy p rotocol  
• IRB guidelines  
• Applicable local and federal  regulations  
Clinical Investigational Plan   Page 26 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  The i nvestigator for each center  may not begin enrollment until the s ponsor has provided written 
approval to do so. The sponsor will not provide approval until it has receive d and approve d 
(when necessary) all required documents, including the IRB approval s of the investigational plan 
and ICF . 
It is acceptable for the i nvestigator  to delegate 1 or more of the above functions to a 
subinvestigator or trained study c oordinator; however, the i nvestigator remains responsible for 
the proper conduct of the clinical investigation, including obtaining informed consent , collecting 
all requir ed data, and submitting accurate and complete e CRFs.  
At each investigational center, appropriate procedures must be followed to maintain participant  
confidentiality according to HIPAA (Health Insurance Portability and Accountability A ct) 
regulations. Each center may have its own internal procedures or requirements for use and 
release of participant  medical information in research studies. Each i nvestigator is responsible 
for obtaining appropriate approvals, consents, or releases of medical information as di ctated by 
their relevant patient privacy laws.  
The study is not transferable to other centers /facilities  attended by the i nvestigator unless 
preapproval is obtained from the applicable  IRB and the s ponsor.  
9.7 Sponsor responsibilities 
The s ponsor’s responsibil ities for this study are to: 
• Select all clinical investigators , investigational centers and other consultants , including 
study monitors, who participate in the study  
• Provide sufficient  training to participating investigational centers to support study 
activities according to the agreements executed with the centers  
• Provide financial support to each center according to the agreements executed with each 
center  
• Follow/promote all regulator y standards according to local/federal regulations for the 
investigational centers, core laboratories, and other participants, and ensure regular investigational center  monitoring to assure compliance with the regulations  
• Retain ownership of all clinical data generated in this study and control the use of the 
data for appropriate purposes only  
• Review and approve publication of study results in the literature  
• Ensure timely and appropriate study registration in a public clinical trial database (eg, www.clinicaltrials.gov
), if applicable  
9.8 Criteria for terminating study  
The s ponsor reserves the right to terminate the study early but intends only to exercise this right 
for valid scientific or administrative r easons or reasons related to the protection of study 
participant s. Investigators  and applicable IRBs will be notified in writing in the event of study 
termination. Reasons for study termination include but are not limited to: 
Clinical Investigational Plan   Page 27 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  • The discovery of an unexpected , significant, or unacceptable risk to the study participant s 
• A decision on the part of the s ponsor to suspend or discontinue commercial distribution 
of the device  
9.9 Criteria for terminating an investigational center  
The s ponsor reserves the right to stop enrollment of participant s at a particular investigational 
center at any time after the study initiation visit f or any of the following reasons : 
• Repeated failure to complete e CRFs  in a timely manner  
• Failure to obtain appropriate informed consent  
• Failure to r eport any study participant  deaths, SAEs, within the  appropriate timeframes  
(See Section 6.2)  
• Loss of or unaccounted product inventory  
• Repeated protocol deviations  
• Lack of study enroll ment or study activity  
10 Reports and Records  
10.1 Records  
All records pertaining to the clinical study will be kept for a minimum of 10 years following the 
date on which the study is terminated or completed. If an i nvestigator wishes to withdraw from 
the responsibility of maintaining these study records, they may transfer the  responsibility to a 
person at the institution who is willing to  accept the responsibility . Such a transfer must  be 
reported to the s ponsor not more than 10 days after the transfer occurs. Alternatively, the 
investigator may transfer the study records to the sponsor after the study is terminated or 
completed.  
10.2 Reporting  requirements  
Investi gators are responsible for the following reporting requirements to the applicable IRB and 
the sponsor:  
• Reporting failure to obtain informed consent before study procedures  
• Progress reports  
• Deviations due to emergency or participant sa fety 
In addition to thi s list, individual IRB may add additional reporting requirements. The principal 
investigator at each investigational center is responsible for ensuring any additional local 
IRB/EC reporting requirements are met, if applicable.  
Invest igators are also responsible for the following reporting requirements to the sponsor:  
• Withdrawal of IRB/EC approval  
• Participant withdrawal  
Clinical Investigational Plan   Page 28 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  The sponsor will be responsible for reporting any device recalls to the IRBs within 30 days of the 
request. Additiona lly, the sponsor will provide a final study report to the Investigators and IRBs 
within 6 months of the study completion or termination. The sponsor will also be responsible for 
registration and posting results on www.clinicaltrials.gov . 
11 Publications  
It is expected that the results of the multicenter study will be submitted for publication . 
Investigators may not publish site -specific data until the multicenter results have  been published. 
The multicenter study results may be published as early outcomes (procedure through 90 days ) 
and late outcomes. ( 180 days  through 365 days ). 
Upon publication of the multicenter results, participating Investigators and/or Institutions may 
submit  their site -specific results  for publication in appropriate scientific conference or journals or 
other professional publications  as outlined in the study contract/agreement .  
  
Clinical Investigational Plan   Page 29 of 2 9 
4666- 001-rB Stryker ENT – C onfidential  12 References  
1  Manjunatha Rao  SV. Cryosurgery on inferior turbinate hypertrophy under topical anaesthesia -  is it 
boon in electricity deprived places? Nat J Otorhinolaryngol Head Neck Surg. 2013;1: 7-9. 
2  Hartley C, Willatt DJ. Cryotherapy in the treatment of nasal obstruction: indications in adults. J  
Laryngol Otol . 1995;109: 729-732. 
3  Chiossone E, Gutierrez JR, Emmanuelli JL . Cryosurgery of the inferior n asal t urbinates. Auris Nasus 
Larynx . 1990; 17:87-93. 
4  Girdhar -Gopal H, Okurowski L, Strome M. An a ssessment of postganglionic c ryoneurolysis for 
managing v asomotor r hinitis. Am J Rhinol  Allergy. 1994;8: 157-164. 
5  Bumsted RM. Cryotherapy for chronic vasomotor rhinitis: technique and patient selection for 
improved results. Larynogoscope . 1984;94:539- 544. 
6  Principato J. A 15- year retrospective of chronic rhinitis and cryosurgery. Ear Nose Throat J . 
1986;65:558 -563. 
7  Mehra YN, Mann SB S, Mehta S, Verma A, Mittal A. Cryosurgery in v asomotor r hinitis  – an analysis 
of 156 p atients. Indian J Otolaryngol . 1990;42 :95-98. 
8  Terao A, Meshitsuka K , Suzaki H, Fukuda S . Cryosurgery on postganglionic f ibers ( posterior nasal 
branches) of the pterygopalatine g anglion for vasomotor r hinitis. Acta Oto laryngol . 1983; 96:139-148. 
9  Arora MML , Khan FA , Mehra YN . Cryodestruction of V idian nerve branches. Indian J  Otolaryngol . 
1980;32: 80-82. 
10  Puhakka H, Rantanen T. Cryotherapy as a method of treatment in allergic and vasomotor rhinitis. J 
Laryngo l Otol. 1977; 91:535-539. 
11  Ozenberger JM. Cryosurgery in c hronic r hinitis. Laryngoscope. 1970;80: 723-734. 
12  Arrinex internal data. Report CT -0003- R FROST CSR rev B. March 22, 2019.  
13  Benninger MB, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence- based review of efficacy for nasal symptoms by class. Ann Allergy 
Asthma Immunol . 2010;104:13- 29. 
14  Downie SR, Andersson M, Rimmer J, et al. Symptoms of persistant allergic rhinitis during a full calendar year in house dust mite- sensitive subjects. Allergy . 2004;59:406- 414. 
15  Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical tria ls 
in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77- 83. 
16  Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98:843- 845. 
17  Rabin R, de Charro F. EQ -5D: a measure of health stat us from the EuroQOL Group. Ann Med. 
2001;33:337- 343. 
18  Szende A, Oppe M, Devlin N. EQ -5D value sets: inventory, comparative review, and user guide. 
EuroQOL Group Monographs. 2010.  
19  Stewart MG, Witsell DL, Smith TL, et al. Development and v alidation of the Nasal Obstruction 
Symptom E valuation  (NOSE) s cale. Otolaryngol  Head Neck Surg . 2004; 130:157‐163.                                                   